No Data
Inspira Technologies Amends Bio-View Debenture and Faces Nasdaq Market Value Deficiency Notice
Inspira Technologies Receives Nasdaq Notice of Non-Compliance With Market Value Requirement
Inspira Expands U.S. Commercial Footprint: Deploys ART100 at a New Premier New York Academic Medical Center, Ranked Top 10 in New York State
Inspira Technologies Sets Up $2 Million At-the-Market Equity Program With A.G.P.
Inspira Technologies to Showcase FDA-Cleared INSPIRA ART100 System at AmSECT 2026 Conference
Inspira Technologies Faces Nasdaq Minimum Bid Price Deficiency, Retains Listing Through Compliance Window